These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 33941104)
1. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study. Kelm M; Schollbach J; Anger F; Wiegering A; Klein I; Germer CT; Schlegel N; Kunzmann V; Löb S BMC Cancer; 2021 May; 21(1):490. PubMed ID: 33941104 [TBL] [Abstract][Full Text] [Related]
2. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. Ayez N; van der Stok EP; Grünhagen DJ; Rothbarth J; van Meerten E; Eggermont AM; Verhoef C Eur J Surg Oncol; 2015 Jul; 41(7):859-67. PubMed ID: 25979624 [TBL] [Abstract][Full Text] [Related]
3. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727 [TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience. Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458 [TBL] [Abstract][Full Text] [Related]
7. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases]. Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia. Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB Oncology; 2013; 85(5):283-9. PubMed ID: 24217184 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062 [TBL] [Abstract][Full Text] [Related]
11. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases. Dexiang Z; Li R; Ye W; Haifu W; Yunshi Z; Qinghai Y; Shenyong Z; Bo X; Li L; Xiangou P; Haohao L; Lechi Y; Tianshu L; Jia F; Xinyu Q; Jianmin X Ann Surg Oncol; 2012 Sep; 19(9):2860-8. PubMed ID: 22526903 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391 [TBL] [Abstract][Full Text] [Related]
13. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973). Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865 [TBL] [Abstract][Full Text] [Related]
14. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Adam R; Delvart V; Pascal G; Valeanu A; Castaing D; Azoulay D; Giacchetti S; Paule B; Kunstlinger F; Ghémard O; Levi F; Bismuth H Ann Surg; 2004 Oct; 240(4):644-57; discussion 657-8. PubMed ID: 15383792 [TBL] [Abstract][Full Text] [Related]
15. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397 [TBL] [Abstract][Full Text] [Related]
17. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702 [TBL] [Abstract][Full Text] [Related]
18. Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection. Liu W; Wang K; Han Y; Liang JY; Li YH; Xing BC Eur J Surg Oncol; 2019 Nov; 45(11):2070-2077. PubMed ID: 31279595 [TBL] [Abstract][Full Text] [Related]
19. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]